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Abstract
Trans fatty acids (TFA) are found naturally in ruminant foods (R-TFA) by 
biohydrogenation in ruminant animals or industrially produced oils (IP-TFA) by 
partial hydrogenation of vegetable or fish oils. The intake of TFA mainly IP-TFA 
is associated with an elevated risk of coronary heart disease (CHD), while some 
prospective cohort studies showed that R-TFA were associated with a lower risk 
for sudden cardiac death (SCD). Our case-control study showed that trans-C18:2 
isomers (IP-TFA) were significantly higher, and palmitelaidic acid (R-TFA) levels 
were lower in patients with acute coronary syndrome (ACS) compared with healthy 
men. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have different 
effects on cardiometabolic risk factors. Delta-5 desaturase (D5D) is a key enzyme 
in the conversion of linoleic acid and alpha-linoleneic acid to arachidonic acid (AA) 
and EPA, respectively. Previous studies reported that low D5D estimated from the 
ratio of AA to dihomo-gamma linolenic acid predicts the incident cardiovascular 
disease. In our cross-sectional study with 436 men with ACS, various atherogenic 
lipid markers such as small dense LDL cholesterol and malondialdehyde-modified 
LDL were significantly inversely associated with D5D activity. We found that the 
EPA/AA may be a superior risk marker than DHA/AA in terms of correlation with 
atherogenic lipid profiles.
Keywords: trans fatty acid, omega-3 fatty acids, delta-5 desaturase,  
coronary heart disease
1. Introduction
Fatty acids (FA) are biologically -active molecules with a wide array of effects 
[1]. FA are classified as saturated or unsaturated on the basis of the absence or 
presence of double bonds. Monounsaturated FA (MUFA) have one double bond; 
polyunsaturated FA (PUFA) have more than one double bond. UFA usually occur 
in the cis configuration, and trans FA (TFA) are UFA containing at least one 
double bond in the trans configuration. FA status can be expressed as composition 
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(each as a percent of total) or as concentration (mass/volume or cell count). 
PUFA with double bonds starting from the sixth position from the methyl end 
of FA are termed as omega-6 series and those from the third position as omega-3 
series. Both omega-3 and omega-6 long-chain PUFA are particularly important 
in humans in order to maintain the function of brain and central nervous system. 
These PUFA are incorporated into the cell membrane. Numerous studies have 
demonstrated that, eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), omega-3 PUFA which are present in fish oils, protect against coronary 
heart disease (CHD) [2]. Harris and von Schacky proposed a metric called the 
“Omega-3 index,” which is the content of EPA + DHA in red blood cell (RBC) 
membranes (expressed as a weight percent of total FA) as a risk factor for death 
from CHD and especially sudden cardiac death (SCD) [3]. The Omega-3 index 
is highly responsive to changes in EPA + DHA intake and the levels in RBCs 
reflect those of other tissues [4]. The Omega-3 index has been used in multiple 
observational cohort and interventional studies around the world. It has been 
associated with the lower risk for CHD, SCD, acute coronary syndromes (ACS), 
all-cause mortality, and other health conditions such as impaired cognitive func-
tion, depression, aggressive behaviors, and bipolar disease [4]. EPA and DHA are 
usually considered as good friends for cardiovascular health, whereas arachidonic 
acid (AA), omega-6 PUFA, is the most important substrate for the synthesis 
of the strongest pro-inflammatory eicosanoids. However, in recent years, the 
complex biochemistry of the eicosanoids, docosanoids, and octadecanoids has 
become clearer, with some omega-6 PUFA metabolites being pro- and others anti-
inflammatory [5, 6]. According to a meta-analysis of prospective cohort studies 
investigating plasma FA (palmitic, oleic, EPA, DHA, and AA) and CHD outcome, 
relative risk and 95% of confidence interval (CI) for CHD for these five FAs was, 
respectively, 1.15 (CI 0.96–1.37), 1.09 (CI 0.97–1.23), 0.78 (CI 0.65–0.94), 0.79 
(CI 0.67–0.93), and 0.83 (CI 0.74–0.92), which suggest the statistically significant 
protective associations with EPA, DHA, and AA [7].
TFA can be found naturally in ruminant foods (R-TFA) by biohydrogenation in 
ruminant animals or industrially produced oils (IP-TFA) by partial hydrogenation 
of vegetable or fish oils. TFA were, initially, considered as safe, and partially hydro-
genated oils (PHO) were responsible for high intakes in the 1970s to 1980s, when 
margarines were advocated over butter to reduce SFA intakes [8]. PHO are contained 
in hard margarine, fatty spreads, and vegetable shortening, deep-fried food, refined 
vegetable oils such as salad oil, and confectionery made using these products [9]. 
Since the early 1990s, however, numerous studies have suggested that high TFA 
intakes may be associated with CHD [10]. Cohort studies and their meta-analyses 
provide concordant evidence that the intake of TFA mainly IP-TFA is associated with 
the elevated risk of CHD [9]. In this chapter, we would like to focus on the role of TFA 
and omega-3 PUFA with special relation on their effects on blood lipids and CHD.
2. IP-TFA and RP-TFA on human health
There is a considerable overlap of TFA in IP-TFA and R-TFA (Figure 1) [11]. 
For fatty acids with 18 carbon atoms, a peak concentration of trans double bonds 
in IP-TFA is found in position 9, as elaidic acid, while a distinct preference for the 
double bond in R-TFA is in position 11.
Numerous studies have suggested that IP-TFA increase LDL cholesterol (LDL-C) 
and lipoprotein (a) [Lp(a)], which is a lipoprotein that promotes atherosclerosis 
and decrease HDL cholesterol (HDL-C), compared with other FA, whereas the 
effect on triglyceride is inconsistent [9, 12]. However, the threshold of effects of 
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TFA may exist in the relationship between TFA and lipid levels, and direct evidence 
of the dose-response relations were not observed from clinical trials when the 
dietary intake of TFAs was as low as <3%E [9, 10]. The consumption of TFA is cur-
rently decreasing in many countries. The average daily TFA intake of the Japanese is 
0.92–0.96 g, or 0.44–0.47%E, which is lower than the <1% target recommended by 
the World Health Organization [9].
The Seven Countries Study (United States (US), Finland, the Netherlands, Italy, 
Yugoslavia, Greece, and Japan) that was initiated in 1958 was the first to show true 
differences in prevalence, incidence, and mortality for CHD among populations 
with different geographical, ethnic, and cultural characteristics. The study reported 
that the intake of elaidic acids, the major IP-TFA, was strongly associated with the 
intake of SFA, serum levels of total cholesterol, and 25-year CHD mortality rates 
[13]. The cross-sectional study of Japanese patients undergoing coronary angiog-
raphy (CAG) that was conducted from 2008 to 2012 failed to show the differences 
in levels of elaidic acid and linoelaidic acids (the two major IP-TFA, although the 
latter can be formed by frying in nonhydrogenated vegetable oils [14]) between 
patients with and without CHD [15]. They showed significantly higher elaidic 
acid levels in younger patients with CHD (≤66 years) compared with elder CHD 
patients and/or patients with metabolic syndrome compared with patients without 
metabolic syndrome [15]. Their group also reported that serum levels of elaidic 
acids were significantly higher in CHD patients with vulnerable plaque evaluated 
by optical coherence tomography compared with those without it (12.9 ± 4.9 vs. 
10.3 ± 4.3 μmol/L, respectively, p = 0.001) [16]. Our case-control study with 66 
male patients with ACS and 49 healthy men, which was conducted from 2013 to 
2014, has reported that total FA and TFA levels were similar between ACS and 
control subjects [17]. Palmitelaidic acid, R-TFA, levels were lower in ACS patients, 
especially in middle-aged ACS patients (0.17 ± 0.06 vs. 0.20 ± 0.06 of total FA, in 
ACS and control, respectively, p < 0.01) (Figure 2). Both proportional and absolute 
concentrations of palmitelaidic acid were significantly directly associated with 
HDL-C (rho = 0.269 and rho = 0.216, respectively), EPA + DHA (rho = 0.458 and 
rho = 0.620, respectively), and EPA + DHA/AA ratios (rho = 0.474 and rho = 0.475, 
respectively). Linoleic trans isomers (total C18:2 TFA), (IP- or frying-derived TFA) 
Figure 1. 
Isomeric distribution of trans-octadecenoic acids in industrially produced and ruminant trans fatty acids 
(mean wt% of trans-18:1 fatty acids) adapted from [11].
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were significantly higher in ACS patients (0.68 ± 0.17 vs. 0.60 ± 0.20 of total FA, in 
ACS and control, respectively) (Figure 2). Absolute concentration of trans-C18:2 
isomers were significantly directly associated with LDL-C and non-HDL-C in 
ACS men. In conclusion of our case-control study, total trans-C18:1 isomers were 
comparable between ACS and control [17]. Differences between ACS and controls 
in C18:1 trans varied by specific C18:1 trans species [17]. Palmitelaidic acid (R-TFA) 
was lower in ACS patients, especially in middle-aged patients. Palmitelaidic acid 
was significantly directly associated with HDL-C, EPA + DHA, and EPA + DHA/AA 
ratios [17]. Linoleic trans isomers (IP-TFAs) were higher in ACS.
The Nurses’ Health Study was initiated in 1976 and enrolled 121,799 female reg-
istered nurses aged 30–55 years in the United States. TFA content in RBC membrane 
was measured in 32,826 women from 1989 to 1990. During 6 years of follow-up, 
166 incident cases of CHD were ascertained and matched with 327 controls. TFA 
in RBC membrane was significantly correlated with dietary intake of TFA (correla-
tion coefficient = 0.44, p < 0.01). Increases in total TFA, trans-C18:1 isomers, and 
trans-C18:2 isomers in RBC membrane were significantly associated with CHD after 
adjustment of covariates [18]. In the Cardiovascular Health Study, a prospective 
cohort of older US adults (≥65 years), plasma phospholipid TFA was measured in 
5888 men and women from 1992 to 1993. Plasma TFA was compared between 214 
cases of fatal CHD and 214 matched controls. Neither plasma trans-C18:1 isomers 
nor palmitelaidic acids but linoelaidic acid (trans-C18:2 isomers) were significantly 
associated with fatal CHD [19]. During 31,494 person-years, 1735 total deaths and 
639 fatal and nonfatal CHD events occurred. Neither plasma trans-C18:1 isomers 
nor palmitelaidic acids but linoelaidic acid (trans-C18:2 isomers) were significantly 
associated with total mortality mainly due to the cardiovascular disease (CVD) and 
Figure 2. 
The comparison of trans fatty acids (TFA) between control and ACS patients. Left panel: comparison in  
whole subjects and Right panel: comparison separated by age. Data are expressed as mean ± standard error 
(SE), and the error bar represents SE. The number of subjects is 49 (<60 years 24; ≥60 years 25) in control and 
67 (<60 years 25; ≥60 years 42) in ACS. *P < 0.05, **p < 0.01 vs. control. Figure was made by Ref. [17].
5Significance of Trans Fatty Acids and Omega-3 Fatty Acids in Japanese Men with Coronary…
DOI: http://dx.doi.org/10.5772/intechopen.93357
increased risk of CHD [20]. Lemaitre et al. measured TFA in RBC membrane in 
179 married cases of out-of-hospital primary cardiac arrest between the ages of 25 
and 74 years, from 1998 to 1999, and 285 age- and sex-matched controls from the 
population-based study [21]. Not trans-C18:1 isomers but linoelaidic acid (trans-
C18:2 isomers) were associated with three-fold increase in risk of primary cardiac 
arrest after adjustment for medical and lifestyle risk factors (odds ratio for inter-
quintile range, 3.1; 95% CI: 1.7–5.4). In the Bergen Coronary Angiography Cohort 
(BECAC), serum TFA (palmitelaidic acid, an R-TFA; and trans C18:1 isomers; 
primarily IP-TFA) were measured in 1367 Norwegian patients underwent CAG 
for suspected CHD during 2000–2001 who were followed throughout 2006 [22]. 
The serum TFA was positively correlated with plasma levels of the NO inhibitor 
asymmetric dimethylarginine (ADMA). They reported that there are no significant 
associations between serum TFA and incident acute myocardial infarction (AMI), 
death from CVD, and all-cause mortality after multivariate adjustments during the 
median of 5.8 years of follow-up [22].
Lemaitre et al. confirmed a correlation between TFA content (C16:1, C18:1, and 
C18:2 isomers) in subcutaneous adipose tissue and estimated TFA intake using a 
self-administered food frequency questionnaire in 51 adult volunteers in 1996 [23]. 
After adjustment for energy intake, age, and body mass index, the correlation coef-
ficients between total TFA and TFA intake were 0.76 (95% CI: 0.51–0.89) among 
men and 0.52 (95% CI: 0.17–0.75) among women [ 23]. A case-control study in 
the United Kingdom compared TFA (trans-C18:1 and C18:2 isomers) in abdominal 
adipose tissue obtained by necropsy from 66 cases of SCD due to the first episode 
of CHD ages of <65 years from 1990 to 1991 and by biopsy from 286 healthy 
age- and sex-matched controls [24]. Not linoelaidic acid (trans-C18:2 isomers) but 
trans-oleic acid (trans-C18:1 isomers) were unexpectedly inversely associated with 
SCD. In an international multicenter study in eight European countries and Israel 
(EURAMIC), adipose tissue aspiration samples were obtained from 671 men with 
AMI, aged of ≤70 years, and 717 men without a history of AMI as control from 1991 
to 1992. The trans-oleic acid (trans-C18:1 isomers) were similar between AMI and 
controls [25]. A case-control study in Norway compared subcutaneous adipose 
tissue TFA between 100 patients with the first episode of AMI and 98 population 
controls, both men and postmenopausal women aged between 45 and 75 years [26]. 
TFA mainly trans-oleic acid (trans-C18:1 isomers) was significantly higher in AMI 
than those in control [26]. A case-control study in Costa Rican population com-
pared adipose tissue TFA between 482 cases aged <75 years with the first episode of 
nonfatal AMI during 1994 and 482 population controls adjusted for sex, age, and 
area of residence [27]. Not trans-C18:1 isomers but high trans-C18:2 isomers were 
significantly associated with the increased risk of nonfatal AMI [27]. We found that 
not trans-C18:1 isomers but trans-C18:2 isomers (IP-TFA) were associated with the 
increased risk of ACS even in Japan [17] that was in good agreement with previous 
reports [18–21, 27].
A 2010 survey of the Hawaii-Los Angeles-Hiroshima Study reported that serum 
elaidic acid concentrations in the native Japanese living in Hiroshima were signifi-
cantly lower than those in the Japanese-Americans living in Los Angeles [28]. The 
study reported a significant association between serum levels of elaidic acid and 
insulin resistance or diabetes among native Japanese [28]. Similarly, our study with 
Japanese and American older men (> age 50) showed that Japanese men had mark-
edly lower levels of elaidic and linoelaidic acids (IP-TFA) while significantly higher 
levels of palmitelaidic acids (R-TFA), compared with American men [29].
The Ludwigshafen Risk and Cardiovascular Health (LURIC) study, a prospec-
tive cohort study of 3259 Caucasians hospitalized for CAG between 1997 and 2000 
in southwestern Germany, was the first to show that higher levels of palmitelaidic 
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acids (R-TFA) in RBC membranes were associated with the lower risk for SCD 
during a median of 10 years of follow-up (Figure 3) and that three trans isomers of 
C18:2n6 (IP-TFA) were not related to fatal cardiovascular outcomes [30]. Total TFA 
levels in LURIC patients (mean 0.96%) were much lower than those in US cohorts 
in the 1990s [31]. According to the TRANSFAIR study, a cross-sectional investiga-
tion in eight countries in Europe, TFA intake is below 1%E and 79% of TFA intake 
was derived from milk and ruminant fat in Germany [32]. Some prospective cohort 
studies showed that R-TFA were associated with the lower risk for incident diabetes. 
In the Cardiovascular Health Study, a prospective cohort study comprising elder 
US adults from 1989 to 1990 from Medicare eligibility lists, plasma phospholipid 
FA were measured in 3736 adults in 1992 [33]. Higher trans-palmitoleate levels 
were associated with slightly lower adiposity and, independently, with higher 
HDL-C levels (1.9% across quintiles; P = 0.040), lower triglyceride levels (−19.0%; 
P < 0.001), a lower total cholesterol/HDL-C ratio (−4.7%; P < 0.001), lower 
C-reactive protein levels (−13.8%; P < 0.05), and lower insulin resistance (−16.7%, 
P < 0.001). Trans-palmitoleate was also associated with a substantially lower 
incidence of diabetes, with multivariate hazard ratios of 0.41 (95% CI, 0.27 to 0.64) 
and 0.38 (CI, 0.24 to 0.62) in quintiles 4 and 5 versus quintile 1 (P for trend <0.001) 
[33]. In the Multi-Ethnic Study of Atherosclerosis (MESA), a cohort of white, black, 
Hispanic, and Chinese Americans, plasma phospholipid FA and metabolic risk 
factors were measured in 2000–2002 in 2281 participants free of baseline diabetes 
[34]. They prospectively assessed the risk of new-onset diabetes (205 cases) from 
baseline to 2005–2007 [34]. Circulating trans-palmitoleate is associated with higher 
LDL-C but also with lower triglycerides, fasting insulin, blood pressure, and inci-
dent diabetes [34]. Large genome-wide association studies have not identified any 
significant genetic determinants of circulating palmitelaidic acid (C16:1 n7t) levels 
Figure 3. 
Adjusted survival curves for sudden cardiac death. Tertiles of palmtelaidic acid (C16:1n7t) were balanced 
for body mass index, LDL-C, HDL-C. log-Triglyceride, log-fibrinogen, smoking, hypertension, diabetes, 
lipid-lowering therapy, and estimated glomerular filtration rate by inverse variance weighting. The inset shows 
the same data on a truncated y axis. Hazard ratios (95% confidence interval) for the second and third tertile 
compared with the first tertile were 0.82 (0.61–1.12) and 0.67 (0.48–0.93), respectively. The p-value of the 
robust score test was 0.043. Reproduced from [30].
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in RBC or plasma phospholipids [35], suggesting that strong endogenous influences 
are not present [31].
According to these findings, dietary intake of R-TFA may be cardioprotective, 
contrary to IP-TFA. Further controlled studies are required to answer the questions 
how a high amount of R-TFA affects human health.
3. Omega-3 fatty acids and CHD
Numerous studies have demonstrated that omega-3 PUFA protect against CVD, 
and the ratios of serum levels of EPA and DHA to AA, omega-6 PUFA have been 
recognized as promising risk markers for CHD [2, 36]. Our case-control study 
showed that the ACS patients had significantly higher levels of saturated FA, 
mainly myristic and palmitic acids, and MUFA, mainly oleic acid, and lower levels 
of omega-3 PUFA, mainly EPA and DHA, and AA, omega-6 PUFA (Figure 4) [17]. 
The Japanese dietary style has markedly changed from the 1960s, and fish to meat 
ratios in food consumption are decreasing in the younger generation, while the 
ratios in the Western countries stayed the same or slightly increased [37]. The age 
profile of the fish/meat >1.0 was ≥40 years in 2000, ≥50 years in 2005 and 2010, 
and ≥ 60 years in 2015 in Japan. The EPA plus DHA to AA ratios were significantly 
lower in ACS patients and were further lower in ACS patients <60 years old 
(Figure 4) [17].
PUFA levels depend on dietary intake, bioavailability, and PUFA metabolism. 
In the biosynthesis of long chain PUFA from precursor PUFA, the crucial enzymes 
include elongase and desaturase (Figure 5) [38, 39]. Delta-5 desaturase (D5D) and 
Figure 4. 
The comparison of trans fatty acids (TFA) between control and ACS patients. Left panel: comparison in whole 
subjects and Right panel: comparison separated by age. Data are expressed as mean ± standard error (SE), 
and the error bar represents SE. The number of subjects is 49 (<60 years 24; ≥60 years 25) in control and 67 
(<60 years 25; ≥60 years 42) in ACS. (A) *p < 0.05, **p < 0.01 *p < 0.001 vs. control. (B) *p < 0.05, **p < 0.01 
*p < 0.001 vs. control<60y; †P < 0.05, ††p < 0.01 †††p < 0.001 vs. ACS < 60y; #P < 0.05, ##p < 0.01 vs. control 
≥60 years. Figure was made by Ref. [17].
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delta-6 desaturase (D6D) are two key enzymes in the synthesis of long-chain PUFA 
and are encoded by fatty acid desaturase 1 (FADS1) and FADS2 genes, respectively 
[39]. Previous studies have reported that the FADS1 gene polymorphism (less 
function) was associated with an increased CHD risk [40, 41]. D5D is involved in 
one step in the conversion of linoleic acid (LA, 18:2 n-6) and alpha-linoleneic acid 
(ALA, 18:3 n-3) to AA (20:4 n-6) and EPA (20:5 n-3), respectively, as the sole enzy-
matic source of endogenous AA and EPA. EPA and DHA are strongly influenced by 
the dietary intake of pre-formed PUFA, and, while human can readily retroconvert 
DHA to EPA, the elongation of ALA to EPA and DHA is minimal [38, 42]. However, 
contrary results have also been very recently reported [43]. The activities of D5D 
cannot be measured directly; generally, they are conventionally estimated from the 
ratio of AA to dihomo-gamma linolenic acid (DGLA, 20:3 n-6) [39, 44–46].
In our cross-sectional study with ACS patients alone, PUFA and various lipid 
markers such as small dense LDL cholesterol (sdLDL-C), malondialdehyde-
modified LDL (MDA-LDL), and remnant lipoprotein cholesterol (RL-C) were 
assessed in 436 men with the first episode of ACS not take any lipid-lowering drugs 
[47]. Approximately 70% of ACS patients had low EPA/AA (<0.41) or DHA/AA 
(<0.93) according to the median levels in Japanese general population [48]. Serum 
levels of LDL-C, apolipoprotein B (apoB), and RL-C were significantly higher in the 
low EPA/AA or DHA/AA groups, while those of triglycerides and MDA-LDL were 
significantly higher in the low EPA/AA group alone. Thus, low EPA/AA is associ-
ated with more atherogenic lipid biomarkers than low DHA/AA. Patients without 
any reperfusion at the culprit coronary artery on the initial CAG had significantly 
lower EPA levels and similar DHA and AA levels compared with the others. The 
levels of LDL-C, non-HDL-C, triglycerides, sdLDL-C, RL-C, MDA-LDL, and 
apoB decreased progressively and those of EPA, DHA, and HDL-C increased as 
D5D increased (Figure 6). While large buoyant LDL-C (lbLDL-C) estimated by 
subtracting the sdLDL-C concentration from the LDL-C concentration, and apoA-1 
did not differ among quartiles of D5D. Previous prospective case-control studies 
Figure 5. 
The omega-3 and omega-6 FA metabolism. ALA, α-linolenic acid; ARA, arachidonic acid; DGLA, dihomo- 
γ-linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; GLA, 
γ-linolenic acid; LA, linoleic acid. Reproduced Ref. [38].
9Significance of Trans Fatty Acids and Omega-3 Fatty Acids in Japanese Men with Coronary…
DOI: http://dx.doi.org/10.5772/intechopen.93357
Figure 6. 
Comparisons of various lipid biomarkers between the quartiles of D5D estimated by AA/DGLA. Data are 
expressed as means ± standard deviation, or median (25% and 75% quartiles) (triglyceride and or RL-C). 
Abbreviations are presented in the main text. Kruskal-Wallis tests and analysis of variance (ANOVA) with 
Tukey’s honest significant difference test was used to identify the differences between the groups. Q1: AA/ 
DGLA < 4.03; Q2: 4.04 ≤ AA/ DGLA < 5.07; Q3: 5.08 ≤AA/ DGLA < 6.29; Q4: AA/DGLA ≥ 6.29. *p < 0.05 
vs. Q1, §p < 0.05 vs. Q2, †p < 0.05 vs. Q3 using Tukey-–Kramer post-hoc test. Figure is made by Ref. [47].
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Figure 7. 
Relative changes in the expression of specific genes determined by quantitative real-time polymerase chain 
reaction (Q-PCR) in olive oil, EPA and DHA supplementation groups. Data are expressed as mean ± standard 
error. Differences within each group were determined by paired t test (**p < 0.01, *p < 0.05). Brackets indicate 
differences between two groups as determined with a 2-factor ANOVA with Tukey honestly significant 
difference correction. CCR6, chemokine (C-C motif) receptor 6; CREB1, cAMP responsive element binding 
protein 1; HIF1A, hypoxia-inducible factor 1-alpha; HMGB1, high mobility group box 1; IL1RN, interleukin 
1 receptor antagonist; IL2RB, interleukin 2 receptor, beta; IRF7, interferon regulatory factor 7; STAT3, signal 
transducer and activator of transcription. Reproduced from [58].
reported that low D5D predict the development of type 2 diabetes [49–51] and 
the risk of CVD [39]. In a Swedish population-based prospective cohort study of 
2009 50-year old men, D5D was reported to have an inverse correlation with CVD 
mortality over a follow-up of 30 years [52]. The association of lower D5D with accu-
mulation of atherogenic sdLDL, MDA-LDL, and RL-C in our study may provide the 
association between lower D5D and atherosclerotic CVD.
Previous studies reported that statins, 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitor, have differential effects on the activities of D5D, 
D6D, and elongase, and any statins increased AA [53]. It is suggested that EPA/AA 
may better reflect the residual risk for CHD following statin treatment than DHA /
AA. Some previous cross-sectional studies have demonstrated that EPA/AA but not 
DHA/AA was significantly associated with ACS [54, 55]. A cohort study of CHD 
patients underwent nonemergency percutaneous coronary intervention (PCI) 
found that lower EPA/AA (but not lower DHA/AA) was significantly associated 
with the incidence of major adverse cardiac events [56]. Our study showed that 
the EPA/AA is a superior risk marker than DHA/AA in terms of correlation with 
atherogenic lipid profiles in ACS patients.
Multiple studies have demonstrated that EPA and DHA have different effects 
on cardiometabolic risk factors [57, 58]. Innes and Calder reviewed 18 random-
ized controlled trials that compare EPA or DHA (>2 g/day and purity ≥90%) and 
placebo on cardiometabolic risk factors [57]. The study durations were between 4 
and 10 weeks. They reported the following results: (1) both EPA and DHA lowered 
triglycerides with DHA having a greater triglyceride-lowering effects than EPA; (2) 
while total cholesterol was largely unchanged by EPA and DHA, DHA increased 
HDL-C, particularly HDL2 and increased LDL-C and LDL particle size; (3) both 
EPA and DHA inhibited platelet activity while DHA improved vascular function 
and lowered heart rate and blood pressure to a greater extent than EPA; and (4) 
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the effects of EPA and DHA on inflammatory markers and glycemic control were 
inconclusive [57]. Tsunoda et al. assessed the effect of a six-week supplementation 
with either olive oil (6 g/day), EPA (1.8 g/day), or DHA (1.8 g/day) on gene expres-
sion in peripheral blood mononuclear cells in healthy men and postmenopausal 
women [58]. EPA but not DHA or olive oil significantly affected the gene expression 
in the interferon signaling, receptor recognition of bacteria and viruses, G protein 
signaling, glycolysis, glycolytic shunting, S-adenosyl-L-methionine biosynthesis, 
cAMP-mediated signaling, as well as many other individual genes including hypoxia 
inducible factor 1 (Figure 7) [58]. They concluded that the effects of EPA and DHA 
were mediated by different pathways in human peripheral blood mononuclear cells 
and that EPA affected cellular immune responses including the interferon signaling 
pathway [58].
4. Conclusion
IP-TFA intake (estimated from plasma levels) is low in Japan, and accordingly, 
there is a little difference in IP-TFA levels between Japanese ACS patients and 
healthy controls. However, a certain IP-TFA is associated with the increased risk of 
CHD even in Japan. Although it is not clear whether R-TFA are cardioprotective or 
not, the ACS patients, especially middle-aged patients showed significantly lower 
levels of R-TFA and omega-3 FA. Although average EPA and DHA levels in Japan are 
much higher than in the United States [59], still higher levels of the marine omega-3 
PUFA are associated with the lower cardiovascular disease risk. However, the 
Japanese dietary style has changed markedly in the younger generation since 1990 
[37, 60]. The lack of fish intake and excessive oils and meat and poultry intakes 
have been recognized in subjects <60 years old in the present Japanese. Decreased 
biosynthesis of long-chain PUFA and imbalance of omega-3 and omega-6 FA are 
clearly associated with atherogenic lipid profiles in Japanese ACS patients. Multiple 
studies have demonstrated that EPA and DHA have different effects on cardio-
metabolic risk factors. The EPA/AA may be a superior risk marker than DHA/AA in 
terms of correlation with atherogenic lipid profiles in clinical practice.
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